Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average recommendation of “Moderate Buy” from the twenty-eight ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, eighteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $817.6667.

REGN has been the topic of a number of recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research report on Monday, June 9th. Sanford C. Bernstein boosted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. State Street Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after buying an additional 42,343 shares during the period. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 1.6% during the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock worth $1,214,585,000 after acquiring an additional 36,821 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after acquiring an additional 89,579 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $591.99 on Friday. The firm has a fifty day moving average of $567.77 and a 200-day moving average of $575.90. The company has a market cap of $62.75 billion, a price-to-earnings ratio of 14.92, a price-to-earnings-growth ratio of 2.00 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $11.56 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.